Scientific publications for BioPredictive non-invasive diagnostics
Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.
121/433
Matches for
“interferon”
-
Changes of non-invasive markers and FibroScan values during HCV treatment.
The recent advent of non-invasive methods for assessment of fibrosis allows…
-
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
…Its level reflects the status of interferon-stimulated genes, which in turn…
-
Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?
…that the new era of interferon-free antivirals will be a reality…
-
A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.
In therapy with standard interferon and ribavirin, five independent risk factors (RF…
-
HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
…Treatment with interferon-based therapy was initiated in 86.3% of cases…
-
Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.
…HCV) nontreated and treated by interferon. The aim was to validate their…
-
Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.
### Background The efficacy of a maintenance therapy in non-responder patients with…
-
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
…Ninety-five interferon-naïve patients with genotype 1 CHC were enrolled in…
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
-
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
…sustained virologic response to pegylated interferon and ribavirin. The study population was…
-
Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C.
-
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
…65 yr treated with pegylated interferon/ribavirin. Group 2: At FT, 58…
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
…who have previously failed pegylated interferon and ribavirin therapy. In addition, recommendations…
-
Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab.
…trigger using antiviral therapy [pegylated interferon plus ribavirin (PEG-IFN/RBV)], and…
-
Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial.
…in a randomized trial of interferon (IFN) using repeated measurements, two biopsies…
-
Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication
-
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
…No patient had received interferon treatment before the liver biopsy sample was…
-
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
-
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
…3. ### Methods Treatment-naive or interferon-experienced UNITY-3 patients with HCV…
-
Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.
Patients infected with hepatitis C virus (HCV) have differing levels of liver…
-
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.
…In replacing interferon-based therapies, all-oral regimens are expected to be…
-
Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
### Background Non-invasive liver fibrosis scores have been proposed as alternatives to…
-
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.
### Background Liver biopsy and virological end points are standard references for assessing…
-
Progression of liver fibrosis among injection drug users with chronic hepatitis C.
Although most hepatitis C virus (HCV) infections are acquired by injection drug…
-
FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.
…HCV were randomized to receive interferon-based therapy for 24 (genotypes 2…
-
Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan.
### Background & Aims Hepatitis C virus (HCV) infection has been shown to be…
-
Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre.
Barriers to management of HCV in injection drug users are related to…
-
Management of the patient with SVR. Review
In the current era of therapy with direct-acting antiviral (DAAs) drugs…
-
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.
### Background & Aims Therapeutic options for patients failing hepatitis C retreatment are limited…
-
HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.
### Background And Aim Three gene polymorphisms, interferon-lambda-3 (IL28B), inosinetriphosphatase (ITPA…
-
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.
### Background Chronic HCV is one of the major causes of morbidity and…
-
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.
…fibrosis who previously failed any interferon-alfa/ribavirin therapy. The aim of…
-
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.
Histological activity reflects the global assessment of basic necroinflammatory lesions and is…
-
Noninvasive prediction of fibrosis in patients with chronic hepatitis C.
-
Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.
The assessment of the fibrotic evolution of chronic hepatitis has always been…
-
Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.
### Background/Aims To compare non-invasive biological liver fibrosis scores, as alternatives…
-
Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.
### Background Direct antiviral agents (DAA) showed very good results in terms of…
-
Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.
### Objectives Liver fibrosis in chronic hepatitis C is related to sex, age…
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
### Background & Aims Chronic hepatitis C is both a virologic and fibrotic disease…
-
Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.
…For genotype 1 patients treated with pegylated interferon and ribavirin, the ICERs…
-
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
### Background & Aims Patients with chronic hepatitis C virus infection and advanced fibrosis…
-
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.
### Objective Liver biopsy, the gold standard for assessing hepatitis C virus (HCV…
-
Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus.
### Background An accurate diagnosis of hepatitis C virus (HCV)-related liver lesions…
-
Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.
…patients, who received ≥80% of interferon (IFN) plus ribavirin therapy, were analyzed…
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
-
Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.
### Background Liver biopsy is an imperfect gold standard for assessing the disease…
-
Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication
Liver fibrosis is a common pathway leading to cirrhosis, which is the…
-
Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.
### Background & Aims Data on liver fibrosis evolution and its involvement in liver…
-
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.
### Background Aims Liver biopsy is the gold standard for assessing hepatitis B…
-
Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C.
### Background Liver fibrosis, now assessed by liver biopsy or using non-invasive…
-
Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.
### Background Previous research has shown variation in the effects of patient factors…
-
Effective use of FibroTest to generate decision trees in hepatitis C.
### Aim To assess the usefulness of FibroTest to forecast scores by constructing…
-
Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt.
In Egypt, as elsewhere, liver biopsy (LB) remains the gold standard to…
-
Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.
### Background Steatosis is common in patients with hepatitis C virus (HCV) infection…
-
Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.
### Background/Aims Non-invasive markers of liver fibrosis have recently been developed…
-
Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.
### Background Assessment of fibrosis progression in chronic liver disease relies upon non…
-
Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection.
FibroTest-ActiTest (FT-AT) has been validated in adults with chronic hepatitis…
-
Biomarkers of liver fibrosis.
Liver biopsy, due to its limitations and risks, is an imperfect gold…
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.
### Background Many blood tests have been proposed as alternatives to liver biopsy…
-
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Key publication
### Background Liver biopsy is thought mandatory for management of patients with hepatitis…
-
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.
-
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
### Objective To determine practices among physicians in Canada for the assessment of…
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.
### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…
-
Ministère des Affaires Sociales et de la Santé Key publication
-
Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study.
### Background Liver biopsy is the reference standard for assessing liver fibrosis and…
-
Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.
### Objectives To evaluate the diagnostic performance of seven non-invasive tests (NITs…
-
[Hepatitis B virus genotypes and evolutionary markers in chronic HBsAG patients in Bujumbura].
### Introduction Hepatitis B virus infection (VHB) is a serious condition which can…
-
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.
### Background And Aims Gilbert syndrome (GS) is genotypically predetermined by UGT1A1*28…
-
Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?
-
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.
### Objective There is a controversy about the performance of blood tests for…
-
Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.
### Introduction Identifying liver fibrosis is important to evaluate the severity of liver…
-
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication
### Background Biopsy is the usual gold standard for liver steatosis assessment. The…
-
Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.
Chronic hepatitis B virus (HBV) infection is a major cause of liver…
-
Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis.
The limitations of liver biopsy (invasive procedure, sampling errors, inter-observer variability…
-
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication
### Background The combination of transaminases (ALT), biopsy, HBeAg and viral load have…
-
Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.
### Objectives To compare plasma antiretroviral concentrations in HIV-HCV co-infected and…
-
[Biomarkers for liver fibrosis: advances, advantages and disadvantages].
Liver cirrhosis in Mexico is one of the most important causes of…
-
Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.
To assess the accuracy of the noninvasive tools, fibrotest (FT) and liver…
-
Finasteride and methadone use and risk of advanced hepatitis C related liver disease.
### Aim We evaluated the association between two medications that alter bioavailable androgen…
-
Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus.
### Introduction Hepatitis C virus (HCV) is the major cause of chronic liver…
-
An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis.
### Background And Aim To assess the clinical and economic outcomes of non…
-
FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?
Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…
-
Usefulness of acoustic radiation force impulse and fibrotest in liver fibrosis assessment after liver transplant.
### Unlabelled Background and rationale. Acoustic radiation force impulse (ARFI) is a non…
-
Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases.
In chronic hepatitis C, biopsy is the gold standard for assessment of…
-
Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.
### Background/Aims In chronic hepatitis C, biopsy is the gold standard for…
-
Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.
### Background/Aims We evaluated the test performance profile (TPP) of blood tests…
-
Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.
### Background Hepatic fibrosis is highly prevalent in individuals with Fontan circulation. FibroSure…
-
Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.
### Background & Aims Non-invasive assessment of liver fibrosis is a challenging area…
-
Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers.
### Objective Studies have shown that patients with failing Fontan circulation may develop…
-
A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.
BACKGROUND: Biochemical markers for liver fibrosis (FibroTest) and necroinflammatory features (ActiTest) are…
-
Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.
### Objective And Methods We assessed the reliability of non-invasive biological scoring…
-
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".
### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…
-
Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.
### Background Low-dose oral methotrexate (MTX) is an effective immunosuppressive therapy for…
-
Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.
### Background & Aims The reliability of transient elastography (TE) to assess liver fibrosis…
-
Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.
### Background And Aims The PGAA index was one of the first composite…
-
Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.
### Background & Aims Liver fibrosis stage is traditionally assessed with biopsy, an imperfect…
-
Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.
### Objectives : Progressive liver injury is a concern in HIV-infected children exposed…
-
[Alpha 2 macroglobulin immunoturbidimetric assays (DakoCytomation reagents) on Roche Diagnostic analysers (Modular P, Cobas Integra). Application to FibroTest-Actic-Test].
### Background Alpha2Macroglobulin (A2M) measure showed a revival since it was introduced into…
-
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication
The aim was to assess the utility of FibroTest-ActiTest (FT-AT…
-
Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
### Unlabelled The association of NAFLD with chronic hepatitis C (CHC) has been…
-
The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).
The aim of this study was to evaluate the diagnostic usefulness of…
-
Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.
### Background Recent longitudinal studies have emphasised the prognostic value of noninvasive tests…
-
Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.
### Background And Aims Real-time shear wave elastography (2D-SWE) is a…
-
Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.
### Background FibroTest (FT) is a validated biomarker of fibrosis. To assess the…
-
Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.
### Background Non invasive methods for fibrosis evaluation remain to be validated longitudinally…
-
Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.
### Unlabelled Males have strikingly increased risk of advanced liver disease. However, the…
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication
### Background No blood test has been shown to be effective in the…
-
Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.
Patients with HIV have a proclivity to develop liver fibrosis, especially when…
-
Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.
Combinations of tests comprising alpha2-macroglobulin, haptoglobin, apolipoprotein Al, gamma-glutamyltransferase, total…
-
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.
SUMMARY: BACKGROUND: Recent studies strongly suggest that due to the limitations and…
-
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication
### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication
This review summarizes the methodological aspects of the interpretation of non-invasive…
-
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.
### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…
-
Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.
### Background & Aims Liver stiffness can be measured noninvasively to assess liver fibrosis…
-
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.
### Background & Aims Coffee or caffeine has been proposed to protect against hepatic…
-
FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication
FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…
-
Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.
### Background African Americans have lower reported likelihood of hepatitis C virus-related…
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
### Background Excessive alcohol consumption may lead to the development of alcohol-related…
Showing the full result list. The page is server-rendered and not paginated.